Related Experiment Video
Updated: Jan 27, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
The Clinical Trial Landscape for Melanoma Therapies
Sonia Wróbel1, Małgorzata Przybyło2, Ewa Stępień3
1Department of Medical Physics, Marian Smoluchowski Institute of Physics, Jagiellonian University, 30-348 Krakow, Poland. soniawrobel1@gmail.com.
Abstract:
(1) Despite many years of research, melanoma still remains a big challenge for modern medicine. The purpose of this article is to review publicly available clinical trials to find trends regarding the number of trials, their location, and interventions including the most frequently studied drugs and their combinations. (2) We surveyed clinical trials registered in the International Clinical Trials Registry Platform (ICTRP), one of the largest databases on clinical trials. The search was performed on 30 November 2018 using the term "melanoma". Data have been supplemented with the information obtained from publicly available data repositories including PubMed, World Health Organization, National Cancer Institute, Centers for Disease Control and Prevention, European Cancer Information System, and many others to bring the historical context of this study. (3) Among the total of 2563 clinical trials included in the analysis, most have been registered in the USA (1487), which is 58% of the total. The most commonly studied drug in clinical trials was ipilimumab, described as applied intervention in 251 trials. (4) An increase in the number of melanoma clinical trials using immunomodulating monoclonal antibody therapies, small molecule-targeted therapies (inhibitors of BRAF, MEK, CDK4/6), and combination therapies is recognized. This illustrates the tendency towards precision medicine.
Insights
Melanoma clinical trials are increasing, with most trials in the USA. Ipilimumab is the most studied drug, reflecting a trend towards precision medicine in cancer treatment.
Area of Science:
- Oncology
- Clinical Research
- Dermatology
Background:
- Melanoma remains a significant medical challenge despite extensive research.
- Understanding trends in clinical trials is crucial for advancing treatment strategies.
Purpose of the Study:
- To review publicly available melanoma clinical trials.
- To identify trends in trial numbers, locations, interventions, and drug combinations.
Main Methods:
- Surveyed the International Clinical Trials Registry Platform (ICTRP) for melanoma trials.
- Conducted search on November 30, 2018, supplementing data from multiple repositories.
- Analyzed 2563 registered clinical trials.
Main Results:
- The USA hosted the majority of trials (58%, 1487 trials).
- Ipilimumab was the most frequently studied intervention (251 trials).
- A rise in immunomodulating monoclonal antibodies, targeted small molecules (BRAF, MEK, CDK4/6 inhibitors), and combination therapies was observed.
Conclusions:
- Melanoma research shows a growing number of clinical trials.
- There is a clear shift towards precision medicine approaches in melanoma treatment.
- Combination therapies and targeted agents are increasingly investigated.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Statistical Software for Data Analysis and Clinical Trials
Trial and Error and Algorithm
Gene Therapy
Group Therapy

